



**Elite Diagnostic Limited**

Unaudited Interim Financial Statements

First Quarter ended September 30, 2022

## Contents

	<b>Page</b>
<b>Directors' report</b>	2
<b>Financial Statements</b>	
Unaudited statement of financial position	3
Unaudited statement of profit or loss and other comprehensive income	4
Unaudited statement of changes in equity	5
Unaudited statement of cash flows	6
Notes to the unaudited interim financial statements	7
List of Directors, Connected Parties and Senior Managers Shareholdings	8 - 9



## Directors' Report

The Board of Directors presents the unaudited financial statements for the first quarter ended September 30, 2022.

Revenue for the quarter increased by \$47.0M from \$140.9M the prior year to \$187.9M. Net profit for the quarter was \$5.8M compared to a loss of \$515,000, which was an improvement of 1229% over the corresponding period in the prior year.

We continue to record increased revenues in most areas which had significantly declined during the height of the Covid-19 pandemic, however unforeseen machine downtime during the period under review has negatively impacted our budgetary projections. An estimated shortfall of \$25M in gross revenues was experienced due to extensive downtime which overlapped the months of August and September.

New measures were implemented during the quarter which resulted in a significant reduction in our direct costs at one of our branches, and these measures are being implemented in stages at our other locations in order to improve our gross margins.

A new CT machine is scheduled to be purchased and installed at our Old Hope Road location early in the new year, and this will not only add to our present revenue streams, but also provide a redundancy for future downtime of the other unit located at our Holborn Road branch.

Total Non-current Assets were \$884.8M compared to \$569.3M, and Total Current Assets were \$134.2M compared to \$102.9M in the corresponding period in the prior year.


Total Current Liabilities were \$133.4M compared to \$89.9M for the comparative period.

The acquisition of the Siemens MRI in 2021 has resulted in the significant variance reflected in the total assets figures reported between the comparative periods.

The above budget increase in our repair costs has caused our liquidity ratio to decline, however the company remains in a strong financial state and is poised to gradually increase market share during the upcoming months with the addition of more equipment and significantly increased marketing.

We take this opportunity to thank our loyal customers, the referring physicians and specialists with whom we partner, all our shareholders, and the dedicated Elite team for their continued hard work and support.

  
\_\_\_\_\_) Director  
**Warren Chung**

  
\_\_\_\_\_) Director  
**Neil Fong**

November 11, 2022

# Elite Diagnostic Limited


## Unaudited statement of financial position

September 30, 2022

	Unaudited September 2022 \$	Reclassified Unaudited September 2021 \$	Reclassified Audited June 2022 \$
<b>Assets</b>			
<b>Non-current assets</b>			
Property, plant and equipment	756,315,454	559,318,014	752,379,008
Right-of-use assets	128,540,200	10,060,097	24,461,857
	<b>884,855,654</b>	<b>569,378,111</b>	<b>776,840,865</b>
<b>Current assets</b>			
Receivables	75,517,360	55,390,690	59,261,920
Prepayments	5,726,144	4,328,245	7,567,596
Cash and cash equivalents	53,030,035	43,257,364	75,890,161
	<b>134,273,539</b>	<b>102,976,299</b>	<b>142,719,677</b>
<b>Total assets</b>	<b>1,019,129,193</b>	<b>672,354,410</b>	<b>919,560,542</b>
<b>Equity</b>			
Share capital	348,898,459	348,898,459	348,898,459
Retained earnings	135,459,976	85,848,731	129,645,128
<b>Total equity</b>	<b>484,358,435</b>	<b>434,747,190</b>	<b>478,543,587</b>
<b>Liabilities</b>			
<b>Non-current liabilities</b>			
Lease liabilities	109,353,102	1,398,488	13,192,272
Long-term loans	291,991,425	146,250,000	323,522,773
	<b>401,344,527</b>	<b>147,648,488</b>	<b>336,715,045</b>
<b>Current liabilities</b>			
Payables and accruals	34,680,052	32,101,040	39,355,367
Short-term loan	2,965,710	-	5,825,615
Current portion of lease liabilities	19,514,698	9,107,692	8,694,162
Current portion of long-term loans	76,265,771	48,750,000	50,426,766
	<b>133,426,231</b>	<b>89,958,732</b>	<b>104,301,910</b>
<b>Total liabilities</b>	<b>534,770,758</b>	<b>237,607,220</b>	<b>441,016,955</b>
<b>Total equity and liabilities</b>	<b>1,019,129,193</b>	<b>672,354,410</b>	<b>919,560,542</b>

The notes on the accompanying pages form an integral part of these financial statements.

Approved for issue by the Directors on November 11, 2022 and signed on its behalf by:

  
 Warren Chung

  
 Neil Fong

# Elite Diagnostic Limited

## Unaudited statement of profit or loss and Other comprehensive income

First Quarter ended September 30, 2022

	Unaudited Three months ended September 30, 2022 \$	Unaudited Three months ended September 30, 2021 \$	Audited year ended June 30, 2022 \$
<b>Income</b>	187,947,201	140,828,437	624,222,166
Direct costs	(53,193,756)	(50,065,132)	(191,958,011)
<b>Gross profit</b>	<b>134,753,445</b>	<b>90,763,305</b>	<b>432,264,155</b>
Administrative expenses	(79,762,102)	(56,991,685)	(242,288,931)
Depreciation	(38,959,383)	(27,272,550)	(107,525,615)
<b>Operating profit</b>	<b>16,031,960</b>	<b>6,499,070</b>	<b>82,449,609</b>
Other income	23,296	137,768	11,261
Finance costs	(8,014,303)	(4,970,935)	(27,331,985)
Loss on foreign exchange	(2,226,105)	(2,180,581)	(6,469,182)
<b>Net profit/(loss) and comprehensive income/(loss) for the period/year</b>	<b>5,814,848</b>	<b>(514,678)</b>	<b>48,659,703</b>
<b>Basic and diluted earnings per share</b>	<b>0.02</b>	<b>(0.001)</b>	<b>0.14</b>

The notes on the accompanying pages form an integral part of these financial statements.

# Elite Diagnostic Limited

## Unaudited statement of changes in equity

First Quarter ended September 30, 2022

	Share Capital \$	Accumulated surplus \$	Total \$
<b>Balance at June 30, 2021 - Audited</b>	348,898,459	112,791,425	461,689,884
Loss for the three months ended September 30, 2021	-	(514,678)	(514,678)
Dividends paid	-	(26,428,016)	(26,428,016)
<b>Transactions with owners</b>	-	(26,428,016)	(26,428,016)
<b>Balance at September 30, 2021</b>	<b>348,898,459</b>	<b>85,848,731</b>	<b>434,747,190</b>
<b>Balance at June 30, 2021 – Audited</b>	348,898,459	112,791,425	461,689,884
<b>Transactions with owners</b>			
Dividends paid	-	(31,806,000)	(31,806,000)
Profit for the year ended June 30, 2022 being total comprehensive income for the year	-	48,659,703	48,659,703
<b>Balance at June 30, 2022 – Audited</b>	348,898,459	129,645,128	478,543,587
Profit for the period ended September 30, 2022 being total comprehensive income for the period - <b>unaudited</b>	-	5,814,848	5,814,848
<b>Balance at September 30, 2022 - Unaudited</b>	<b>348,898,459</b>	<b>135,459,976</b>	<b>484,358,435</b>

The notes on the accompanying pages form an integral part of these financial statements.

# Elite Diagnostic Limited

## Unaudited statement of cash flows

First Quarter ended September 30, 2022

	Unaudited Three months ended September 30, 2022 \$	Unaudited Three months ended September 30, 2021 \$	Audited Year ended June 30, 2022 \$
<b>Cash flows from operating activities:</b>			
Profit/(loss) before tax	5,814,848	(514,678)	48,659,703
Adjustments for:			
Depreciation and amortisation	38,959,383	27,272,550	107,525,615
Foreign exchange loss on lease liabilities	3,038,572	-	-
Interest expense	8,014,303	4,970,935	27,331,985
	<b>55,827,106</b>	<b>31,728,807</b>	<b>183,517,303</b>
Increase in receivables	(16,255,440)	(13,623,858)	(17,495,088)
Decrease/(increase) in prepayments	1,841,452	2,915,108	(324,243)
(Decrease)/increase in payables and accruals	(4,675,315)	2,309,640	9,563,967
<b>Cash provided by operations</b>	<b>36,737,803</b>	<b>23,329,697</b>	<b>175,261,939</b>
Interest paid	(8,014,303)	(4,970,935)	(27,331,985)
<b>Net cash provided by operations</b>	<b>28,723,500</b>	<b>18,358,762</b>	<b>147,929,954</b>
<b>Cash flow from investing activities</b>			
Purchase of property, plant and equipment	(35,139,644)	(9,240,017)	(275,793,213)
<b>Net cash used in investing activities</b>	<b>(35,139,644)</b>	<b>(9,240,017)</b>	<b>(275,793,213)</b>
<b>Cash flow from financing activities</b>			
Dividends paid	-	(26,428,016)	(31,806,000)
Short-term loan	(2,859,905)	-	5,825,615
Repayment of loans	(5,692,343)	-	(11,050,461)
Repayment of lease liabilities	(7,891,734)	(3,427,160)	(13,209,529)
Proceeds on long-term loan	-	-	190,000,000
<b>Net cash (used in)/provided by financing activities</b>	<b>(16,443,982)</b>	<b>(29,855,176)</b>	<b>139,759,625</b>
<b>Net (decrease)increase in cash and cash equivalents</b>	<b>(22,860,126)</b>	<b>(20,736,431)</b>	<b>11,896,366</b>
<b>Cash and cash equivalents at beginning of year</b>	<b>75,890,161</b>	<b>63,993,795</b>	<b>63,993,795</b>
<b>Cash and cash equivalents at end of year</b>	<b>53,030,035</b>	<b>43,257,364</b>	<b>75,890,161</b>

The notes on the accompanying pages form an integral part of these financial statements.

# Elite Diagnostic Limited

## Notes to the unaudited interim financial statements

September 30, 2022

### 1. General information and nature of operations

Elite Diagnostic Limited was incorporated under the laws of Jamaica on February 12, 2012 and is domiciled in Jamaica. The company commenced operations in August 2013. The company's principal place of business is located at 1b Holborn Road, Kingston 5.

The company provides diagnostic imaging services.

### 2. Statement of compliance

#### a Basis of preparation

These financial statements have been prepared in accordance with International Financial Reporting Standards (IFRS) IAS 34, Interim Financial Reporting.

The interim financial report is to be read in conjunction with the audited financial statements for the year ended June 30, 2022. The significant accounting policies adopted are consistent with those of the audited financial statements for the year ended June 30, 2022.

#### b Critical judgements and sources of estimation uncertainty

The preparation of these financial statements requires management to make estimates and assumptions that affect the amounts reported in the financial statements. These estimates are based on historical experience and management's best knowledge of current events and actions. Actual results may differ from these estimates and assumptions.

### 3. Share capital

	Unaudited Three months ended September 30, 2022 \$	Unaudited Three months ended September 30, 2021 \$
Authorised ordinary units of no par value	<b>Unlimited</b>	<b>Unlimited</b>
Issued ordinary units of no par value	<b>353,400,000</b>	<b>353,400,000</b>
Stated capital: Issued and fully paid ordinary stocks of no par value	<b>348,898,459</b>	<b>348,898,459</b>

#### Earnings per shares

	Unaudited Three months ended September 30, 2022 \$	Unaudited Three months ended September 30, 2021 \$
Profit/(loss) attributable to shareholders	<b>5,814,848</b>	<b>(514,678)</b>
Weighted average number of shares	<b>353,400,000</b>	<b>353,400,000</b>
Earnings per shares	<b>0.02</b>	<b>(0.001)</b>



# Elite Diagnostic Limited

## List of Directors, Connected Parties and Senior Managers Shareholdings

As at September 30, 2022

### Directors and connected parties

#### Directors

Names	Position	Shares Held	Percentages %
Steven Gooden	Chairman	35,289,628	9.9857
Warren Chung	Non-Executive Director	778,355	0.22025
Neil Fong	Executive Director	140,000	0.03962
Andre Ho Lung	Non-Executive Director	161,494	0.04572
Kevin Donaldson	Non-Executive Director	140,000	0.03962
Mark Kerr-Jarrett	Non-Executive Director	NIL	NIL
Quentin Hugh Sam	Non-Executive Director	824,573	0.2333
William Mahfood	Non-Executive Director	172,025	0.0487
<b>Combined Directors Holdings</b>		<b>37,506,075</b>	<b>10.61292</b>

#### Connected parties

Connected parties	Connected to	Shares Held	Percentages %
Excel Investments	Warren Chung and Neil Fong	86,674,897	24.5760
Barnett Limited	Mark Kerr-Jarrett	15,515,994	4.3905
NCB Capital Markets Limited	Steven Gooden	66,028,392	18.6838
<b>Combined Connected Parties Holdings</b>		<b>168,219,283</b>	<b>47.6503</b>

#### Combined Holdings

**205,725,358**      **58.26322**

### Senior Managers Shareholdings

Names	Position	Shares Held	Percentages %
Neil Fong	Manager	140,000	0.0396
Marjorie Miller	Manager	-	-
<b>Combined Senior Managers Holdings</b>		<b>140,000</b>	<b>0.0396</b>

#### Connected parties

Connected parties	Connected to	Shares Held	Percentages %
Excel Investments	Warren Chung and Neil Fong	86,674,897	24.5260
		<b>86,674,897</b>	<b>24.5260</b>

#### Combined Connected Party Holdings

**86,814,897**      **24.5656**

#### Total issued capital

**353,400,000**

---

# Elite Diagnostic Limited

## List of Top 10 Shareholders

As at September 30, 2022

---

### Top 10 Shareholders

Names	Share Held	Percentages %
1. Excel Investments (Connected to Warren Chung and Neil Fong)	86,674,897	24.5260
2. NCB Capital Markets Limited (Connected to Steven Gooden)	66,028,392	18.6838
3. Steven Gooden	35,289,628	9.9857
4. JCSD Trustee Services Limited - Sigma Optima	31,438,024	8.8959
5. Barnett Limited (Connected to Mark Kerr-Jarrett)	14,513,589	4.1068
6. Damian Chin-You	8,000,000	2.2637
7. West Indies Radiology Outsourcing Ltd.	15,515,994	4.3905
8. Everton J. Smith	5,402,466	1.5287
9. QWI Investments Limited	4,894,392	1.3849
10. Lizette Mowatt	3,703,632	1.0480
<b>Total units owned by top 10 Shareholders</b>	<b>271,461,014</b>	<b>76.8140</b>
<b>Total Issued Capital</b>	<b>353,400,000</b>	